Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase.

Autor: Peraire, Joaquim, García-Pardo, Graciano, Chafino, Silvia, Sánchez, Alba, Botero-Gallego, Maryluz, Olona, Montserrat, Espineira, Sonia, Reverté, Laia, Skouridou, Vasso, Peiró, Óscar M., Gómez-Bertomeu, Fréderic, Vidal, Francesc, O' Sullivan, Ciara K., Rull, Anna
Předmět:
Zdroj: European Journal of Medical Research; 4/5/2024, Vol. 29 Issue 1, p1-15, 15p
Abstrakt: Background: COVID-19 pneumonia causes hyperinflammatory response that culminates in acute respiratory syndrome (ARDS) related to increased multiorgan dysfunction and mortality risk. Antiviral-neutralizing immunoglobulins production reflect the host humoral status and illness severity, and thus, immunoglobulin (Ig) circulating levels could be evidence of COVID-19 prognosis. Methods: The relationship among circulating immunoglobulins (IgA, IgG, IgM) and COVID-19 pneumonia was evaluated using clinical information and blood samples in a COVID-19 cohort composed by 320 individuals recruited during the acute phase and followed up to 4 to 8 weeks (n = 252) from the Spanish first to fourth waves. Results: COVID-19 pneumonia development depended on baseline Ig concentrations. Circulating IgA levels together with clinical features at acute phase was highly associated with COVID-19 pneumonia development. IgM was positively correlated with obesity (ρb = 0.156, P = 0.020), dyslipemia (ρb = 0.140, P = 0.029), COPD (ρb = 0.133, P = 0.037), cancer (ρb = 0.173, P = 0.007) and hypertension (ρb = 0.148, P = 0.020). Ig concentrations at recovery phase were related to COVID-19 treatments. Conclusions: Our results provide valuable information on the dynamics of immunoglobulins upon SARS-CoV-2 infection or other similar viruses. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: